Nanotechnology-Enabled Therapeutics for Global Viral Diseases: From COVID-19 to Emerging Viral Infections
Abstract
The threat of viral disease remains one of the biggest concerns regarding global public health, as is evident from the recent global pandemic caused by the coronavirus and the repeated outbreaks of new pathogens like influenza virus, Ebola virus, Zika virus, Nipah virus, monkey pox virus, and coronaviruses that are pathogenic. Traditional approaches to antiviral therapy may pose certain limitations, like poor bioavailability, systemic toxicity, mutation rate of the virus, multiple drug resistance, and the inability of drugs to target tissues specifically. The development of nanotechnology has been a breakthrough solution in overcoming the limitations posed by traditional methods. This review aims at assessing the latest advancements in the field of nanotechnology in terms of developing therapeutic interventions in viral diseases, especially COVID-19 and other emerging viral infections. These approaches improve drug stability, bioavailability, controlled drug delivery, and immunogenicity, all while minimizing toxicity in the body. Despite the fact that there are several promising applications for nanomedicines in both pre-clinical and clinical studies, issues pertaining to biosafety, scalability, and regulation prevent their full clinical implementation. Nanotechnology-based treatments constitute a paradigm shift within antiviral medicine with respect to their integration of targeted drug delivery, immune manipulation, and precision medicine. It is important that further interdisciplinary efforts, regulation, and clinical trials contribute to the development of such nanotechnologies to combat viral pandemics in the present and in the future.
Keywords: Nanotechnology; Viral infections; COVID-19; Antiviral drug delivery; Nanovaccines.
Keywords:
Nanotechnology, Viral infections, Antiviral drug delivery, NanovaccinesDOI
https://doi.org/10.22270/jddt.v16i9.8013References
1. Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical–physical applications to nanomedicine. Molecules. 2019;25(1):112. 10.3390/molecules25010112. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Nasrollahzadeh M, Sajadi SM, Sajjadi M, and Issaabadi Z. An introduction to nanotechnology,” In: Interface science and technology, Elsevier, 2019;28:1–27. 10.1016/B978-0-12-813586-0.00001-8.
3. Rasmi Y, Saloua K, Nemati M, Choi J. Recent progress in nanotechnology for COVID-19 prevention, diagnostics and treatment. Nanomaterials. 2021;11(7):1788. 10.3390/nano11071788. [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems. Polymers. 2023;15(7):1596. 10.3390/polym15071596. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Campos EVR, et al. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. J Nanobiotechnol. 2020;18(1):125. 10.1186/s12951-020-00685-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Pal, R., Ghosh, B., Dutta, P., Mukeshkumar Shah, T., & Singh, A. (2026). Cutting-edge nano novel drug delivery carriers (NDCs) for tuberculosis (TB) management: insights into clinical trials and patent landscape. Journal of Microencapsulation, 1–31. https://doi.org/10.1080/02652048.2026.2684955
7. Araste F, Bakker AD, Zandieh-Doulabi B. Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. J Nanopart Res. 2023;25(11):229. 10.1007/s11051-023-05867-3. [Google Scholar]
8. Hasanzadeh A, et al. Nanotechnology against COVID-19: immunization, diagnostic and therapeutic studies. J Control Release. 2021;336:354–74. 10.1016/j.jconrel.2021.06.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Sorbello M, Rosenblatt W, Hofmeyr R, Greif R, Urdaneta F. Aerosol boxes and barrier enclosures for airway management in COVID-19 patients: a scoping review and narrative synthesis. Br J Anaesth. 2020;125(6):880–94. 10.1016/j.bja.2020.08.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Tarfaoui M, Nachtane M, Goda I, Qureshi Y, Benyahia H. 3D printing to support the shortage in personal protective equipment caused by COVID-19 pandemic. Materials. 2020;13(15):3339. 10.3390/ma13153339. [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Dhar A, et al. Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2. Immunol Res. 2024;72(1):14–33. 10.1007/s12026-023-09416-x. [DOI] [PubMed] [Google Scholar]
12. Aadil KR, et al. Nanotechnology assisted strategies to tackle COVID and long-COVID. BioNanoSci. 2025;15(2):217. 10.1007/s12668-025-01812-x. [Google Scholar]
13. Pachani RV, Shah TM, Soni D. Advances in peptide- and antibody-targeted nanocarriers for cancer therapy and imaging. J Popul Ther Clin Pharmacol. 2021;28(1):392–419. doi:10.53555/3sadmc24. Journal of Population Therapeutics
14. Joseph MM, Nair JB, Arya JS. Integrated utilization of functional nanomaterials for COVID-19 monitoring, prevention, and diagnostic strategies. Res Biomed Eng. 2025;41(1):23. 10.1007/s42600-025-00404-8. [Google Scholar]
15. Palestino G, García-Silva I, González-Ortega O, Rosales-Mendoza S. Can nanotechnology help in the fight against COVID-19? Expert Rev Anti-Infect Ther. 2020;18(9):849–64. 10.1080/14787210.2020.1776115. [DOI] [PubMed] [Google Scholar]
16. Ruiz‐Hitzky E, et al. Nanotechnology responses to COVID‐19. Adv Healthc Mater. 2020;9(19):2000979. 10.1002/adhm.202000979. [DOI] [PubMed] [Google Scholar]
17. Weiss C, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–406. 10.1021/acsnano.0c03697. [DOI] [PubMed] [Google Scholar]
18. Tang Z, Zhang X, Shu Y, Guo M, Zhang H, Tao W. Insights from nanotechnology in COVID-19 treatment. Nano Today. 2021;36:101019. 10.1016/j.nantod.2020.101019. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Yang D. Application of nanotechnology in the COVID-19 pandemic. IJN. 2021;16:623–49. 10.2147/IJN.S296383. [DOI] [PMC free article] [PubMed] [Google Scholar]
20. Mishra BK, et al. COVID-19 created chaos across the globe: three novel quarantine epidemic models. Chaos, Solitons Fractals. 2020;138:109928. 10.1016/j.chaos.2020.109928. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Hao Y, et al. The origins of COVID‐19 pandemic: a brief overview. Transbound Emerg Dis. 2022;69(6):3181–97. 10.1111/tbed.14732. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Alwine JC, Casadevall A, Enquist LW, Goodrum FD, Imperiale MJ. A critical analysis of the evidence for the SARS-CoV-2 origin hypotheses. mSphere. 2023;8(2):e0011923. 10.1128/msphere.00119-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8. 10.1016/j.jare.2020.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Dhand R, Li J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):651–9. 10.1164/rccm.202004-1263PP. [DOI] [PMC free article] [PubMed] [Google Scholar]
25. WHO. Independent assessment of the origins of SARS-CoV-2 from the scientific advisory group for the origins of novel pathogens (SAGO). Geneva, Switzerland, 27 Jun 2025. [Online]. Available: https://bit.ly/SAGO-SARS-CoV-2
26. Choi H, et al. Current understanding of the surface contamination and contact transmission of SARS-CoV-2 in healthcare settings. Environ Chem Lett. 2021;19(3):1935–44. 10.1007/s10311-021-01186-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. 10.1016/j.ijantimicag.2020.105924. [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Abdelrahman Z, Li M, Wang X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses. Front Immunol. 2020;11:552909. 10.3389/fimmu.2020.552909. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423. 10.7759/cureus.7423. [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Hui DSC, Chan MCH, Wu AK, Ng PC. Severe acute respiratory syndrome (SARS): epidemiology and clinical features. Postgrad Med J. 2004;80(945):373–81. 10.1136/pgmj.2004.020263. [DOI] [PMC free article] [PubMed] [Google Scholar]
31. WHO. WHO COVID-19 dashboard, World health organization data. Available: https://data.who.int/dashboards/covid19/cases?n=o. Accessed 22 Jun 2025. [Online].
32. Colaneri M, et al. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clin Microbiol Infect. 2020;26(8):1094.e1-1094.e5. 10.1016/j.cmi.2020.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Geng Y, Wang Y. Stability and transmissibility of SARS‐CoV‐2 in the environment. J Med Virol. 2023;95(1):e28103. 10.1002/jmv.28103. [DOI] [PMC free article] [PubMed] [Google Scholar]
34. Van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7. 10.1056/NEJMc2004973. [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Mahmoudi A, et al. Application of nanotechnology in air purifiers as a viable approach to protect against Corona virus. IET Nanobiotechnol. 2023;17(4):289–301. 10.1049/nbt2.12132. [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Naikoo GA, et al. Nanomaterials‐based sensors for the detection of COVID‐19: a review. Bioeng Transla Med. 2022;7(3):e10305. 10.1002/btm2.10305. [DOI] [PMC free article] [PubMed] [Google Scholar]
37. Rai M, et al. Nanotechnology as a shield against COVID-19: current advancement and limitations. Viruses. 2021;13(7):1224. 10.3390/v13071224. [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Alzyood M, Jackson D, Aveyard H, Brooke J. COVID‐19 reinforces the importance of handwashing. J Clin Nurs. 2020;29(15–16):2760–1. 10.1111/jocn.15313. [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Souri M, et al. Anti-COVID-19 nanomaterials: directions to improve prevention, diagnosis, and treatment. Nanomaterials. 2022;12(5):783. 10.3390/nano12050783. [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Verma S, Panday D, Vasanthi AV, Sahoo S, Roli, Yadav A, Ghosh B, Pal R. Micro novel carriers: reshaping tuberculosis therapy by targeting alveolar macrophages, reducing drug resistance, and shortening treatment durations—a 2020-2025 comprehensive review. Recent Patents Nanotechnol. 2026. doi:10.2174/0118722105421253260515204927.
41. Huang Y, et al. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Sig Transduct Target Ther. 2024;9(1):34. 10.1038/s41392-024-01745-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Salleh A, et al. The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action. Nanomaterials. 2020;10(8):1566. 10.3390/nano10081566. [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Pilaquinga F, Morey J, Torres M, Seqqat R, Piña MDLN. Silver nanoparticles as a potential treatment against SARS‐CoV ‐2: a review. WIREs Nanomed Nanobiotechnol. 2021;13(5):e1707. 10.1002/wnan.1707. [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Govind V, et al. Antiviral properties of copper and its alloys to inactivate COVID-19 virus: a review. Biometals. 2021;34(6):1217–35. 10.1007/s10534-021-00339-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Jagaran K, Singh M. Nanomedicine for COVID-19: potential of copper nanoparticles. Biointerface Res Appl Chem. 2020;11(3):10716–28. 10.33263/BRIAC113.1071610728. [Google Scholar]
46. Dave P, Raval B, Mori D, Dudhat K. Targeted nanotechnology in bone cancer: integrating stimuli responsive drug delivery and artificial intelligence for personalized therapy. Nano Trends. 2026 Jan 10:100182.
47. Hosseini M, Behzadinasab S, Chin AWH, Poon LLM, Ducker WA. Reduction of infectivity of SARS-CoV-2 by Zinc oxide coatings. ACS Biomater Sci Eng. 2021;7(11):5022–7. 10.1021/acsbiomaterials.1c01076. [DOI] [PubMed] [Google Scholar]
48. Wolfgruber S, et al. Antiviral activity of Zinc oxide nanoparticles against SARS-CoV-2. IJMS. 2023;24(9):8425. 10.3390/ijms24098425. [DOI] [PMC free article] [PubMed] [Google Scholar]
49. He L, et al. Using nano-selenium to combat Coronavirus Disease 2019 (COVID-19)? Nano Today. 2021;36:101037. 10.1016/j.nantod.2020.101037. [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Khurana A, et al. Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond. J Drug Deliv Sci Technol. 2023;86:104663. 10.1016/j.jddst.2023.104663. [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Yoosefian M, Sabaghian H. Silver nanoparticle-based drug delivery systems in the fight against COVID-19: enhancing efficacy, reducing toxicity and improving drug bioavailability. J Drug Target. 2024;32(7):794–806. 10.1080/1061186X.2024.2356147. [DOI] [PubMed] [Google Scholar]
52. Lopes TS, Alves GG, Pereira MR, Granjeiro JM, Leite PEC. Advances and potential application of gold nanoparticles in nanomedicine. J Cell Biochem. 2019;120(10):16370–8. 10.1002/jcb.29044. [DOI] [PubMed] [Google Scholar]
53. Hasan M, et al. Crest to trough cellular drifting of green-synthesized Zinc oxide and Silver nanoparticles. ACS Omega. 2022;7(39):34770–8. 10.1021/acsomega.2c02178. [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Jahan I, Erci F, Cakir-Koc R, Isildak I. Microwave-irradiated green synthesis of metallic silver and copper nanoparticles using fresh ginger (Zingiber officinale) rhizome extract and evaluation of their antibacterial potentials and cytotoxicity. Inorg Nano-Met Chem. 2021;51(5):722–32. 10.1080/24701556.2020.1808017. [Google Scholar]
55. Kantipudi S, et al. Enhanced wound healing activity of Ag–ZnO composite NPs in Wistar Albino rats. IET Nanobiotechnol. 2018;12(4):473–8. 10.1049/iet-nbt.2017.0087. [DOI] [PMC free article] [PubMed] [Google Scholar]
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Abhishek Kumar, Anamika Gaurishankar Parihar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.